Vical Stockholders Approve Reverse Stock Split and Merger with Brickell
August 30, 2019 11:54 ET
|
Vical Incorporated
• Merger Transaction Expected to Close August 31, 2019 SAN DIEGO, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Vical Incorporated (“Vical”) (Nasdaq:VICL) announced that its stockholders voted to approve the...
Vical and Brickell Announce Merger Agreement
June 03, 2019 03:00 ET
|
Vical Incorporated
Combined Company Well-Capitalized with Approximately $35 Million in Cash and up to $25 Million in Near-Term R&D FundingPivotal Phase 3 Clinical Trials for Brickell’s Lead Product Candidate,...
Vical to Discontinue Clinical Development of VL-2397 as it Considers Near Term Strategic Alternatives
February 19, 2019 17:45 ET
|
Vical Incorporated
SAN DIEGO, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that it has decided to discontinue the Phase 2 clinical trial of VL‑2397 that was initiated in the first...